Author Archive
Kenneth Gutiérrez
Director, Product
Kenneth Gutiérrez is the Director of Product at Docuvera, where he leads product strategy for a platform that helps pharmaceutical companies author, govern, and reuse regulated content. Kenneth describes his approach as “science background, business foreground” — a perspective built on rational drug design and pre-clinical academic research in biochemistry at Texas Tech University and a STEM MBA from the Rawls College of Business, and refined through 15+ years of life sciences experience spanning early-stage drug research and enterprise SaaS product management, including more than five years at Agilent Technologies leading customer success onboarding and global pricing strategy for life sciences software.
At Docuvera, Kenneth leads the full product organization — including product managers and product owners across agile delivery — overseeing platform direction, web experience, and integrations.

Kenneth’s product focus is squarely on the challenges that matter most to regulated teams: governance-first structured content authoring, ePI readiness, IDMP-aligned content strategy, health authority interactions, and interoperable content workflows. He is a regular contributor to industry conversations on these topics, presenting alongside the Docuvera team at DIA webinars and forums — where his dual fluency in scientific practice and product strategy grounds technical discussions in real operational requirements.
Read Docuvera’s AI and structured content readiness framework at https://docuvera.com/blog/how-to-assess-ai-and-structured-content-readiness/ or connect with Kenneth on LinkedIn https://www.linkedin.com/in/kenneth-glenn-galloway/
Posts by Kenneth Gutiérrez
How pharma teams can prepare for structured product information, FHIR readiness, and EU ePI standard…
What Pharma Companies Need to Know About ePI FHIR When the European medicines regulatory network a…
How EU ePI and FDA SPL Create Parallel Labeling Workflows A director of Regulatory Affairs at a mi…
Global growth in pharma increases complexity before it increases value. This article explains why gl…



